5Kane JM, Capon MH, Saha AZ, et al. Efficay and safety of aripi-prazale and haloperidol versus placebo in patients with schizophre-nia and scahizoaffective disorderf J]. J Clin Psyiatry,2002,63(9):763 -771.
3Sabine M. J. M, Gysele S, Jeanne P, et al. Antipsychotics and the risk of sudden cardiac death[J]. Arch Intern Med, 2004,164 : 1293.
4Daniel E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders[J]. The American Journal of Medicine,2005, 118(sup2): 164.
5Stacy R, Charles M, Beasley, et al. Effects of intramuscular olanzapine vs. halpperidol and placebo on QTc intervals in acutely agitated patients[J]. Psychiatry Research, 2003,119:113.
6Charles H, Alissa R, Danielle H, et al. Schizophrenia and increased risks of cardiovascular disease[J]. American Heart Journal,2005,150(6) :1115.
7E Kevin, Jeremy N. Drug-induced proarrhythmia and use of QTc-prolonging agents.. Clues for clinicians[J]. Heart Rhythm,2005,11 (2) :51.
9Harrigan EP, Miceli JJ,Anziano R,et al. Arandomized evaluation of the effects of six antipsyehotic agents on QTc,in the absence and presence of metabolic inhibition[J]. J Clin Psychopharmacol, 2004, 24 (1): 62 - 69.
10Stimmel GL, Guitierrez MA, Lee V, Ziprasidone: an atypical antipsy- choticdrug for the treatment of schizophrenia[J]. Clinical Therapeutics, 2002,24(1) :21 - 37.
